These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 32178288)

  • 1. Dendritic Cells and Immunogenic Cancer Cell Death: A Combination for Improving Antitumor Immunity.
    Lamberti MJ; Nigro A; Mentucci FM; Rumie Vittar NB; Casolaro V; Dal Col J
    Pharmaceutics; 2020 Mar; 12(3):. PubMed ID: 32178288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell Vaccines.
    Vandenberk L; Belmans J; Van Woensel M; Riva M; Van Gool SW
    Front Immunol; 2015; 6():663. PubMed ID: 26834740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Personalized Dendritic Cell Vaccines-Recent Breakthroughs and Encouraging Clinical Results.
    Mastelic-Gavillet B; Balint K; Boudousquie C; Gannon PO; Kandalaft LE
    Front Immunol; 2019; 10():766. PubMed ID: 31031762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale for the Combination of Dendritic Cell-Based Vaccination Approaches With Chemotherapy Agents.
    Truxova I; Hensler M; Skapa P; Halaska MJ; Laco J; Ryska A; Spisek R; Fucikova J
    Int Rev Cell Mol Biol; 2017; 330():115-156. PubMed ID: 28215530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer.
    Versteven M; Van den Bergh JMJ; Marcq E; Smits ELJ; Van Tendeloo VFI; Hobo W; Lion E
    Front Immunol; 2018; 9():394. PubMed ID: 29599770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel Dendritic Cell-Based Vaccination Protocol to Stimulate Immunosurveillance of Aggressive Cancers.
    Nigro A; Montico B; Casolaro V; Dal Col J
    Methods Mol Biol; 2019; 1884():317-333. PubMed ID: 30465213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenic Apoptosis as a Novel Tool for Anticancer Vaccine Development.
    Montico B; Nigro A; Casolaro V; Dal Col J
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29462947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type I interferons and dendritic cells in cancer immunotherapy.
    Sprooten J; Agostinis P; Garg AD
    Int Rev Cell Mol Biol; 2019; 348():217-262. PubMed ID: 31810554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma.
    Garg AD; Vandenberk L; Koks C; Verschuere T; Boon L; Van Gool SW; Agostinis P
    Sci Transl Med; 2016 Mar; 8(328):328ra27. PubMed ID: 26936504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of dendritic cells for peptide-based vaccination in cancer immunotherapy.
    Salem ML
    Methods Mol Biol; 2014; 1139():479-503. PubMed ID: 24619701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potentiation of immunologic responsiveness to dendritic cell-based tumor vaccines by recombinant interleukin-2.
    Shimizu K; Fields RC; Redman BG; Giedlin M; Mulé JJ
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S67-75. PubMed ID: 10685663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dendritic cell-based immunotherapy.
    Sabado RL; Balan S; Bhardwaj N
    Cell Res; 2017 Jan; 27(1):74-95. PubMed ID: 28025976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decoding cancer cell death-driven immune cell recruitment: An in vivo method for site-of-vaccination analyses.
    Fang S; Agostinis P; Salven P; Garg AD
    Methods Enzymol; 2020; 636():185-207. PubMed ID: 32178819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancing Dendritic Cell Therapy in Solid Tumors with Immunomodulating Conventional Treatment.
    Belderbos RA; Aerts JGJV; Vroman H
    Mol Ther Oncolytics; 2019 Jun; 13():67-81. PubMed ID: 31020037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances and perspectives of dendritic cell-based active immunotherapies in follicular lymphoma.
    Cox MC; Lapenta C; Santini SM
    Cancer Immunol Immunother; 2020 Jun; 69(6):913-925. PubMed ID: 32322910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenic Cell Death Induced by Ginsenoside Rg3: Significance in Dendritic Cell-based Anti-tumor Immunotherapy.
    Son KJ; Choi KR; Lee SJ; Lee H
    Immune Netw; 2016 Feb; 16(1):75-84. PubMed ID: 26937234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dendritic Cells in Anticancer Vaccination: Rationale for Ex Vivo Loading or In Vivo Targeting.
    Baldin AV; Savvateeva LV; Bazhin AV; Zamyatnin AA
    Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32150821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies to Improve the Efficacy of Dendritic Cell-Based Immunotherapy for Melanoma.
    Hargadon KM
    Front Immunol; 2017; 8():1594. PubMed ID: 29209327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low Photosensitizer Dose and Early Radiotherapy Enhance Antitumor Immune Response of Photodynamic Therapy-Based Dendritic Cell Vaccination.
    Doix B; Trempolec N; Riant O; Feron O
    Front Oncol; 2019; 9():811. PubMed ID: 31508370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.